公开(公告)号：US08609437B2

公开(公告)日：2013-12-17

申请号：US12812394

申请日：2009-01-21

Applicant: Anthony T. Yeung ,  Jeffrey Tokar

Inventor： Anthony T. Yeung ,  Jeffrey Tokar

IPC: G01N33/68 ,  G01N33/00 ,  G01N33/543 ,  C40B40/10 ,  C40B40/00

CPC classification number: G01N33/487 ,  C12Q1/68 ,  C12Q1/6886 ,  C12Q2600/158 ,  G01N33/00 ,  G01N33/48

Abstract: Compositions and methods for use in methods and kits for the detection of an increased risk of pancreatic cancer are provided. Cyst fluid samples isolated from patients that are positive for at least three of the following markers, mucin 1, mucin 2, mucin 5AC, mucin 5B, mucin 6, CEA CAM 1, CEACAM 5, CEACAM 6, CEACAM 7, CEACAM 8, S100-A6, S100-A8, S100-A9 and S100-A11 indicate that such patients are at greater risk for the development of pancreatic cancer when compared to cyst fluid samples isolated from patients lacking these markers.

Abstract translation: 提供了用于检测胰腺癌风险增加的方法和试剂盒中的组合物和方法。 对于至少三种以下标记为阳性的患者分离的囊液液样品，粘蛋白1，粘蛋白2，粘蛋白5AC，粘蛋白5B，粘蛋白6，CEA CAM 1，CEACAM 5，CEACAM 6，CEACAM 7，CEACAM 8，S100 -A6，S100-A8，S100-A9和S100-A11表明，与从缺乏这些标记物的患者分离的囊肿液样品相比，这些患者胰腺癌的发展风险更高。

公开(公告)号：US20130306000A1

公开(公告)日：2013-11-21

申请号：US13471776

申请日：2012-05-15

Applicant: Roger A. Coulombe ,  Kent Reed

Inventor： Roger A. Coulombe ,  Kent Reed

IPC: C12Q1/68 ,  C07K16/40 ,  A01K67/02 ,  C40B30/04 ,  C07H21/04 ,  C40B40/06 ,  C40B40/10

CPC classification number: C12Q1/6888 ,  A01K67/027 ,  A01K2227/30 ,  A01K2267/02 ,  C12Q2600/124 ,  C12Q2600/156

Abstract: The present disclosure includes methods of improving the quality of poultry and the efficiency of its production. Specifically, single nucleotide polymorphisms (SNPs) have been identified in signature domains and conserved residues found in α-class turkey Glutathione S-Transferase (GSTA) genes. These SNPS correlate with aflatoxin resistance in turkeys. Thus, methods of screening for the relevant SNPs using polynucleotides and anti-peptide antibodies, kits that include these tools, and methods of breeding aflatoxin resistant flocks are provided herein.

Abstract translation: 本公开内容包括提高家禽质量及其生产效率的方法。 具体来说，在α类火鸡谷胱甘肽S-转移酶（GSTA）基因中发现的特征域和保守残基中鉴定了单核苷酸多态性（SNP）。 这些SNPS与火鸡中的黄曲霉毒素抗性相关。 因此，本文提供了使用多核苷酸和抗肽抗体筛选相关SNP的方法，包括这些工具的试剂盒以及育种黄曲霉毒素蛋白的方法。

公开(公告)号：US08563476B2

公开(公告)日：2013-10-22

申请号：US13535215

申请日：2012-06-27

Applicant: James W. Lillard, Jr.

Inventor： James W. Lillard, Jr.

IPC: A61K39/00 ,  A61K39/395 ,  C40B30/04 ,  C40B40/10 ,  G01N33/53 ,  C12Q1/68 ,  G01N33/566

CPC classification number: C07K16/24 ,  A61K2039/505 ,  C07K16/2866

Abstract: A method for detecting an inflammatory disease in a subject is disclosed. The method comprises the steps of (a) detecting a level of expression of one or more inflammatory disease markers in a biological sample obtained from the subject; and (b) comparing the level of expression of said one or more inflammatory disease markers in the biological sample to a normal level of expression of the one or more inflammatory disease markers, wherein the one or more inflammatory disease markers comprise one or more markers selected from the group consisting of CXCL9, CXCL10, CXCL11, CXCL13, CXCR3 and CXCR5. Also disclosed are a method for monitoring the course of treatment for an inflammatory disease in a subject and a kit for detecting an inflammatory disease in a subject.

Abstract translation: 公开了一种用于检测受试者的炎性疾病的方法。 该方法包括以下步骤：（a）检测从受试者获得的生物样品中的一种或多种炎性疾病标志物的表达水平; 和（b）将生物样品中所述一种或多种炎性疾病标志物的表达水平与一种或多种炎症性疾病标志物的正常水平的表达进行比较，其中所述一种或多种炎性疾病标志物包括选择的一种或多种标志物 来自CXCL9，CXCL10，CXCL11，CXCL13，CXCR3和CXCR5。 还公开了一种用于监测受试者的炎性疾病的治疗过程的方法和用于检测受试者的炎性疾病的试剂盒。

公开(公告)号：US20130116133A1

公开(公告)日：2013-05-09

申请号：US13350480

申请日：2012-01-13

Applicant: James Douglas Watson ,  Richard Llewellyn Sydney Forster ,  Damian Jay White

Inventor： James Douglas Watson ,  Richard Llewellyn Sydney Forster ,  Damian Jay White

IPC: C40B30/04 ,  C40B40/10

CPC classification number: G01N33/57434

Abstract: Methods for diagnosing the presence of prostate cancer in a subject are provided, such methods including detecting the levels of expression of multiple polypeptide biomarkers in a biological sample obtained from the subject and comparing the levels of expression with predetermined threshold levels. Levels of expression of at least two of the polypeptide markers that are above the predetermined threshold levels are indicative of the presence of prostate cancer in the subject. Determination of the expression levels of specific combinations of biomarkers can also be used to determine the type and/or stage of prostate cancer.

公开(公告)号：US20130085079A1

公开(公告)日：2013-04-04

申请号：US13631567

申请日：2012-09-28

Applicant: SOMALOGIC, INC.

Inventor： Rosalynn Dianne GILL ,  Stephen Alaric WILLIAMS ,  Alex A.E. STEWART ,  Robert MEHLER ,  Trudi FOREMAN ,  Britta SINGER

IPC: C40B30/04 ,  C40B40/06 ,  C40B40/10

CPC classification number: G01N33/6872 ,  G01N33/6893 ,  G01N2333/51 ,  G01N2800/32 ,  G01N2800/50 ,  G01N2800/60

Abstract: The present disclosure includes biomarkers, methods, devices, reagents, systems, and kits for the evaluation of risk of a caradiovascular (CV) Event within 5 years. In one aspect, the disclosure provides biomarkers that can be used alone or in various combinations to evaluate risk of a CV event within 5 years. In another aspect, methods are provided for evaluating risk of a CV event within 5 years in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 1. In a further aspect, methods are provided for evaluating the risk of a CV, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 2. In a further aspect, methods are provided for evaluating the risk of a CV event in an individual, generally within 5 years, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 3.

公开(公告)号：US20130085072A1

公开(公告)日：2013-04-04

申请号：US13631331

申请日：2012-09-28

Applicant: LOS ALAMOS NATIONAL SECURITY, LLC

Inventor： Andrew M. Bradbury ,  Csaba Kiss ,  Sara D'Angelo ,  Fortunato Ferrara ,  Leslie A. Naranjo ,  Tiziano Gaiotto

IPC: C40B30/04 ,  C40B40/10 ,  C07K16/00 ,  C40B10/00

CPC classification number: G01N33/6854 ,  C07K16/005 ,  C07K16/1289 ,  C07K2317/52 ,  C07K2317/622 ,  C07K2317/92 ,  C07K2319/00 ,  C12Q1/02 ,  G01N33/6845

Abstract: Described herein are methods that combine phage and yeast display to create polyclonal antibodies that are renewable, and when amplified over 100 million fold, maintain diversity without loss of representation of any of the antibodies present. The antibody representation remains essentially constant, as confirmed by deep sequencing. The provided methods allow generation, use and propagation of polyclonal antibodies, without concern that representation is lost. Furthermore, because the derivation of the polyclonal pool is carried out in vitro using phage and yeast display, it is possible in various embodiments to eliminate reactivities that are considered undesirable. Additionally, the polyclonal pool can be enriched for higher affinity antibodies.

Abstract translation: 本文描述了将噬菌体和酵母显示组合以产生可再生的多克隆抗体的方法，并且当扩增超过1亿倍时，保​​持多样性而不损失任何存在的抗体。 通过深度测序证实，抗体表现基本上保持恒定。 所提供的方法允许产生，使用和繁殖多克隆抗体，而不用担心丢失表示。 此外，由于多克隆池的衍生是使用噬菌体和酵母显示在体外进行的，所以在各种实施方案中可以消除被认为是不合需要的反应性。 此外，多克隆池可以富集以获得更高亲和力的抗体。

公开(公告)号：US20130065782A1

公开(公告)日：2013-03-14

申请号：US13592267

申请日：2012-08-22

Applicant: Rachel M. Ostroff ,  Stephen Alaric Williams ,  Michael Riel-Mehan ,  Edward N. Brody ,  Alex A.E. Stewart ,  Shintaro Kato

Inventor： Rachel M. Ostroff ,  Stephen Alaric Williams ,  Michael Riel-Mehan ,  Edward N. Brody ,  Alex A.E. Stewart ,  Shintaro Kato

IPC: C40B30/04 ,  G06F19/00 ,  G01N33/574 ,  C12Q1/68 ,  C40B40/06 ,  C40B40/10

CPC classification number: G01N33/57438 ,  C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N2333/4703 ,  G01N2333/4706 ,  G01N2333/521 ,  G01N2333/70503 ,  G01N2333/78 ,  G01N2333/805 ,  G01N2333/8121 ,  G01N2333/96433 ,  G01N2333/96494 ,  G16B25/00

Abstract: The subject disclosure concerns methods for evaluation of renal cell carcinoma (RCC). Such methods include a method of determining of a diagnosis of the individual as having or not having RCC; determination of a prognosis of a future course of RCC; determination of disease burden; or determination of recurrence of RCC in an individual who had been apparently cured of RCC. The methods each involve the detection of the value of at least one biomarker of Table 1. The biomarker value is used, in some of the methods, to determine whether the individual does or does not demonstrate evidence of disease, and in another method, to determine the degree or a score indicative of the individual's extent of disease.

公开(公告)号：US20130053280A1

公开(公告)日：2013-02-28

申请号：US13697019

申请日：2011-05-09

Applicant: Koshin Hamasaki ,  Toshiro Saito

Inventor： Koshin Hamasaki ,  Toshiro Saito

IPC: C40B60/12 ,  C40B40/10 ,  C40B50/14 ,  C40B40/06

CPC classification number: C12Q1/6806 ,  C12Q1/6834 ,  G01N21/05 ,  G01N21/554 ,  G01N21/648 ,  G01N33/54346 ,  C12Q2565/518 ,  C12Q2565/507 ,  C12Q2563/155

Abstract: Disclosed is a technique for binding microparticles to patterned bonding pads of a metal (e.g., gold) formed on a support. The microparticles each carry a nucleic acid synthetase or DNA probe immobilized thereon for capturing a nucleic acid sample fragment. The technique involves forming, on a support surface, a film having a thickness equivalent to that of the bonding pads; controlling the size of microparticles with respect to the size of bonding pads; and thereby immobilizing microparticles each bearing a single nucleic acid sample fragment to the bonding pads in a one-to-one manner in a grid form. This allows high-density regular alignment and immobilization of many types of nucleic acid fragment samples on a support and enables high-throughput analysis of nucleic acid samples. Typically, immobilization of microparticles at 1-micrometer intervals easily provides a high density of 106 nucleic acid fragments per square millimeter.

公开(公告)号：US20130045895A1

公开(公告)日：2013-02-21

申请号：US13642200

申请日：2011-04-19

Applicant: Rudolf Maria De Wildt ,  Mark Liddament ,  Nicola Ramsay ,  Oliver Schon ,  Adriaan Allart Stoop

Inventor： Rudolf Maria De Wildt ,  Mark Liddament ,  Nicola Ramsay ,  Oliver Schon ,  Adriaan Allart Stoop

IPC: C07K16/00 ,  C40B40/08 ,  C07H21/04 ,  C40B40/10

CPC classification number: C07K16/00 ,  C07K16/18 ,  C07K16/22 ,  C07K16/241 ,  C07K16/247 ,  C07K16/3007 ,  C07K2317/567 ,  C07K2317/569 ,  C07K2317/92

Abstract: The invention relates to amino acid residues within an immunoglobulin light chain amino acid sequence (VL) which stabilize the monomeric state of the immunoglobulin single variable domain. In particular, but not exclusively, the invention describes a number of mutations that stabilize the monomeric state of DPK9 framework Vκ domain antibodies.

Abstract translation: 本发明涉及稳定免疫球蛋白单可变结构域的单体状态的免疫球蛋白轻链氨基酸序列（VL）内的氨基酸残基。 具体而非排他地，本发明描述了许多稳定DPK9构架V＆kgr的单体状态的突变; 结构域抗体。

公开(公告)号：US20130045893A1

公开(公告)日：2013-02-21

申请号：US13522230

申请日：2011-01-14

Applicant: Deborah Roberts ,  Mina Hoorfar ,  Sina Jomeh ,  Rony Das

Inventor： Deborah Roberts ,  Mina Hoorfar ,  Sina Jomeh ,  Rony Das

IPC: C12M1/34 ,  C40B40/10 ,  C40B40/06 ,  C40B60/12

CPC classification number: G01N33/54306 ,  G01N33/54366

Abstract: Apparatuses for determining whether a substance is carried in a fluid are disclosed. One such apparatus includes a body having: a plurality of spaced-apart capture surfaces configured to contact the fluid and capture the substance from the fluid; and a plurality of fluid guiding surfaces spaced apart by a predetermined distance from respective at least portions of respective ones of the plurality of capture surfaces. Another such apparatus includes: a fluid conduit to direct flow of the fluid; and at least one element removably positioned in the fluid conduit and having at least one capture surface configured to contact the fluid and capture the substance from the fluid.

Abstract translation: 公开了用于确定物质是否携带在流体中的装置。 一种这样的装置包括主体，其具有：多个间隔开的捕获表面，其构造成接触流体并从流体捕获物质; 以及与所述多个捕获表面中的相应的至少一部分间隔开预定距离的多个流体引导表面。 另一种这样的装置包括：流体导管，用于引导流体的流动; 以及至少一个元件，其可移除地定位在所述流体导管中并且具有构造成接触所述流体并从所述流体捕获所述物质的至少一个捕获表面。